This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
UnitedHealth Group, Inc. is the largest health care services company in the world, serving over 50 million individuals in the United States as of 2019 and over 5 million internationally. The company provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point of service plans (POS), preferred provider organizations (PPOs), and managed fee-for-service programs. UnitedHealth has the largest and most diverse membership base within the managed-care organization market, which gives it significant competitive advantages. It also has built its prescription drug business through OptumRx division, with the acquisition of Catamaran in 2015.
Brokers Suggest Investing in UnitedHealth (UNH): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in UnitedHealth (UNH). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
UnitedHealth Group (UNH) Rises Higher Than Market: Key Facts
by Zacks Equity Research
UnitedHealth Group (UNH) reached $305.75 at the closing of the latest trading day, reflecting a +1.68% change compared to its last close.
Will CVS Health's Formulary Move Boost Its Weight Management Program?
by Moumi Mondal
CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.
Is AI the Key to UnitedHealth's Market Growth and Cost Control?
by Kaibalya Pravo Dey
UNH ramps up AI use to cut costs, boost efficiency, and reshape healthcare workflows, but legal risks remain.
UnitedHealth Group (UNH) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
The latest trading day saw UnitedHealth Group (UNH) settling at $302.01, representing a -1.69% change from its previous close.
Two Healthcare Heavyweights, One Winner: UnitedHealth or CVS Health?
by Kaibalya Pravo Dey
CVS gains steam as rising margins, strong Medicare results, and cost cuts set it apart from UNH.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Should SPDR Dow Jones Industrial Average ETF (DIA) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for DIA
Can Optum Offset UnitedHealth's Health Benefits Growth Woes?
by Zacks Equity Research
Optum drives growth for UNH as rising Medicare Advantage costs pressure its health benefits unit.
UnitedHealth Group Incorporated (UNH) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
UnitedHealth (UNH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
CVS Health's MBR Improves: Can It Sustain Amid Elevated Cost Trends?
by Moumi Mondal
CVS posts its first favorable MBR in quarters, but elevated cost trends test its ability to sustain the gains.
UnitedHealth Group (UNH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
UnitedHealth Group (UNH) concluded the recent trading session at $310.56, signifying a +2.23% move from its prior day's close.
UnitedHealth's Medical Membership Rises: Can It Maintain the Momentum?
by Zacks Equity Research
UNH's medical membership tops 50M amid rising demand. However, high Medicare costs cloud its growth outlook.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Wall Street Bulls Look Optimistic About UnitedHealth (UNH): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for UnitedHealth (UNH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
UnitedHealth Group (UNH) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
UnitedHealth Group (UNH) concluded the recent trading session at $300.38, signifying a -0.28% move from its prior day's close.
UnitedHealth to Curtail Medicare Advantage Costs: Margin Boost Ahead?
by Zacks Equity Research
UNH's CEO pledges reform after rare earnings miss as rising Medicare Advantage costs squeeze margins and spook investors.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
UnitedHealth Declines 40.4% YTD: Here's Why it's Still Not a Bargain
by Kaibalya Pravo Dey
UNH shares have plunged YTD, but regulatory risks, cost pressures and earnings downgrades keep it far from a bargain.
UnitedHealth Group (UNH) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
In the most recent trading session, UnitedHealth Group (UNH) closed at $298.17, indicating a +0.02% shift from the previous trading day.
Elevance Looks Cheap Now: But is it Time to Buy or Dodge?
by Kaibalya Pravo Dey
Strong capital efficiency and commercial growth make ELV appealing, but regulatory and cost headwinds keep investors cautious.
UnitedHealth Group (UNH) Stock Moves -0.37%: What You Should Know
by Zacks Equity Research
UnitedHealth Group (UNH) closed the most recent trading day at $295.57, moving -0.37% from the previous trading session.
UnitedHealth vs. Elevance: Which Healthcare Stock Has More Upside?
by Kaibalya Pravo Dey
ELV outpaces UNH with stronger earnings, leaner costs and clearer guidance, making it the healthcare stock with more upside right now.
Wall Street Analysts Think UnitedHealth (UNH) Is a Good Investment: Is It?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), UnitedHealth (UNH) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?